Pull to refresh
Logo
Slate Medicines merges with Fulcrum Therapeutics to reach Nasdaq

Slate Medicines merges with Fulcrum Therapeutics to reach Nasdaq

Money Moves

A failed drugmaker becomes the public listing for a $245 million bet on the next migraine target

Yesterday: Slate and Fulcrum announce merger and $245M financing

Overview

Updated 2 hours ago

Fulcrum Therapeutics spent two years watching its two lead drugs fail. On August 17, 2026, the shell that remained agreed to merge with Slate Medicines, a privately held migraine startup, in an all-stock deal paired with a $245 million private placement.

The combined company keeps Slate's name, trades under the ticker 'SLTE,' and pours the cash into one experimental antibody meant to prevent migraine by hitting a target the current drug class leaves untouched. Slate's backers will own 95% of the result.

Why it matters

The deal hands a next-generation migraine antibody a public listing and $245 million to challenge today's CGRP drugs, which don't work for everyone.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$245M
Private placement
Oversubscribed round led by Frazier Life Sciences, funding the company into 2029.
95%
Slate ownership of combined company
Pre-merger Fulcrum holders keep 5% in this reverse merger.
2029
Cash runway
The combined balance is expected to fund operations into 2029.
$130M
Slate Series A
Slate's February 2026 launch round, six months before the merger.
SLTE
New Nasdaq ticker
Fulcrum's 'FULC' becomes 'SLTE' when the deal closes.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 4 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Organizations Involved

Timeline

September 2024 August 2026

5 events Latest: Yesterday
Tap a bar to jump to that date
  1. Slate and Fulcrum announce merger and $245M financing

    Latest Merger

    The two firms agree to an all-stock reverse merger paired with a $245 million placement. The combined company trades as 'SLTE' and is funded into 2029.

  2. Fulcrum drops its second drug

    Corporate

    Fulcrum discontinues pociredir for sickle cell disease after FDA safety concerns and opens a review of strategic options.

  3. Rival anti-PACAP drug posts positive data

    Clinical

    Lundbeck reports positive Phase 2b results for bocunebart, its own anti-PACAP migraine antibody, validating the target Slate is chasing.

  4. Slate Medicines launches

    Financing

    Slate emerges from RA Capital's incubator with a $130 million Series A to develop anti-PACAP antibodies for migraine prevention.

  5. Fulcrum's lead drug fails Phase 3

    Clinical

    Losmapimod misses its goals in a muscular dystrophy trial. Fulcrum's stock falls about 70% in a day, from $8.85 to $2.60.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

May 2018

Aimovig and the CGRP migraine revolution (2018)

The FDA approved Aimovig (erenumab) from Amgen and Novartis, the first drug designed specifically to prevent migraine by blocking CGRP, a signaling molecule in the brain. Emgality, Ajovy, and Vyepti followed within two years.

Then

A class of injectable antibodies gave millions of patients a preventive option that older repurposed pills could not match.

Now

CGRP drugs grew into a multibillion-dollar market, but a large share of patients still respond poorly or not at all.

Why this matters now

Slate is betting the next gains come from PACAP, a separate pathway, for the patients CGRP drugs leave behind.

2020

Aduro Biotech's reverse merger into Chinook (2020)

Aduro Biotech, a public company whose cancer immunotherapy programs had stalled, merged with privately held Chinook Therapeutics, which developed kidney-disease drugs. Chinook took over the public listing and Aduro's cash.

Then

The deal gave Chinook a Nasdaq listing without a traditional IPO and refocused the company on new science.

Now

Novartis acquired Chinook in 2023 for up to $3.5 billion, one of the more successful biotech reverse mergers.

Why this matters now

It is the template for this deal: a failed public biotech becomes the vehicle for a well-funded private company's science.

2023–2024

Lundbeck's anti-PACAP proof of concept (2023)

Lundbeck's antibody Lu AG09222 cut migraine days versus placebo in a mid-stage trial, with results later published in the New England Journal of Medicine. It was the first clinical proof that blocking PACAP could prevent migraine.

Then

The data validated PACAP as a real drug target, distinct from CGRP.

Now

Lundbeck advanced the drug, now called bocunebart, into a larger Phase 2b program that read out positively in 2026.

Why this matters now

Slate's whole thesis rests on this mechanism; Lundbeck both proves it works and is the company to beat.

Sources

(7)